Fennec Pharmaceuticals Inc.

NASDAQ:FENC

Biotechnology

Healthcare
$13.33 -1.34%

-$0.12 today

Market cap
$470.62M
Beta
1.08
P/E (TTM)
-36.3
EPS (TTM)
-$0.24
52W Low $5.65High $10.45

Volume 0.59M

Average 0.26M

FENC Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Fennec Pharmaceuticals Inc.NASDAQ: FENC

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $26K fell 33.3% year over year, ahead of the -59.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 2499.9% from the prior quarter. Over 3 fiscal years it compounded at -11.6% a year.

Context

  • Depreciation & amortization amounted to 0.2% of revenue in FY2025, down 1.8 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -33.3% holds above the trailing-twelve-month pace of -59.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$26K+2499.9% QoQ
Last fiscal yearDec 2025
$103K-89.3% YoY
LTMMar 2026
$103K-59.6% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-33.3%——
1 year-89.3%——
3-year CAGR-11.6%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
103K USD
Year-over-year change
-89.3%
4-year CAGR
+59.3%

Depreciation & Amortization vs competitors

How FENC compares with its peers on the latest reported figures

  • FENC's LTM Mar 2026 depreciation & amortization of $103K is the smallest of the 11 companies compared; the peer median is $934K.
  • Its year-over-year change of -59.6% is the 10th highest of 11, against a peer median of +2.1%.
  • Depreciation & amortization amounts to 0.2% of revenue for FENC, versus a peer median of 18.6%.
FENC Competitors Peer median
Depreciation & Amortization for FENC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$6.32M -1.1%+23.7%—
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$4.95M +56.5%+19.6%7.2%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$3.13M -28.6%+0.0%27.9%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$2.42M +13.1%+32.0%136.2%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$1.53M +180.4%+0.4%9.2%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$718K -3878.9%——
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$334K +5.4%+13.8%1.0%
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$265K -23.0%-13.8%—
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$263.36K +65.0%+17.8%—
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$226K -16.3%+27.5%383.1%
FENCFennec Pharmaceuticals Inc.LTM Mar 2026$103K -59.6%-11.6%0.2%
Peer median (excluding FENC) $934K+2.1%+17.8%18.6%

Competitors are the stored peer set for FENC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(17.35M)(23.71M)(16.05M)(436K)(10.27M)
Depreciation & Amortization16K149K287K959K103K
Deferred Income Tax00000
Stock-Based Compensation4.01M4.22M5.35M5.06M7.03M
Change in Working Capital(138K)(509K)(8.17M)(7.33M)(15.09M)
Accounts Receivables0(1.55M)(7.27M)(7.87M)(12.66M)
Inventory0(576K)(1.58M)579K(1.3M)
Accounts Payables00001.42M
Other Working Capital(138K)1.61M683K(35K)(2.55M)
Other Non-Cash Items(769K)1.8M1.43M28.73M5.76M
Operating Cash Flow(14.22M)(18.06M)(17.14M)26.98M(12.47M)
Capital Expenditures00000
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow00000
Debt Repayment5M20.17M5M(13M)(19.82M)
Common Stock Issued33K00045.01M
Common Stock Repurchased0(194K)(78K)(176K)0
Dividends Paid00000
Other Financing Activities(55K)753K1.72M(439K)(2.57M)
Financing Cash Flow4.98M20.73M6.64M(13.62M)22.63M
Effect of Forex Changes00000
Net Change in Cash(9.24M)2.67M(10.51M)13.37M10.15M
Free Cash Flow(14.22M)(18.06M)(17.14M)26.98M(12.47M)

Fennec Pharmaceuticals Inc.

NASDAQ:FENC

Intrinsic Alpha fair value

Locked

Current Price

$13.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.